[{"orgOrder":0,"company":"Microbiotix","sponsor":"Paratus Investment","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Microbiotix","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Microbiotix \/ Paratus Investment","highestDevelopmentStatusID":"5","companyTruncated":"Microbiotix \/ Paratus Investment"}]

Find Clinical Drug Pipeline Developments & Deals by Microbiotix

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : The proceeds will be used to begin the first-ever human clinical trial of phage therapy in Korea.

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          September 03, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Paratus Investment

                          Deal Size : $14.5 million

                          Deal Type : Series B Financing

                          blank